X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, Janssen will develop, manufacture, and commercialize CAR T-based cell therapy candidates with Simcha’s novel proprietary decoy-resistant IL-18 (DR-18) for a set number of programs.
Lead Product(s): CAR T-based Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Simcha Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 08, 2024
Details:
The collaboration will initially focus on developing an at home self-administered subcutaneous version of a lead oncology asset, and up to four additional targets using Elektrofi's innovative formulation technology platform.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Elektrofi
Deal Size: $793.0 million Upfront Cash: $18.0 million
Deal Type: Collaboration January 03, 2024
Details:
Under the terms of the agreement, LCB will grant Janssen an exclusive, worldwide license for the development and commercialization of LCB84, a Trop2 directed ADC which is currently being investigated for advanced solid tumors.
Lead Product(s): LCB84,Undisclosed
Therapeutic Area: Oncology Product Name: LCB84
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Recipient: LegoChem Biosciences
Deal Size: $1,700.0 million Upfront Cash: $100.0 million
Deal Type: Licensing Agreement December 26, 2023
Details:
Under the Agreement, Janssen is conducting Phase 2b trial of JNJ-2113 (formerly known as PN-235), a first-in-class targeted oral peptide designed to selectively block the IL-23 receptor, in moderately to severely active ulcerative colitis.
Lead Product(s): JNJ-2113
Therapeutic Area: Gastroenterology Product Name: JNJ-2113
Highest Development Status: Phase IIProduct Type: Peptide
Recipient: Protagonist Therapeutics
Deal Size: $987.5 million Upfront Cash: $50.0 million
Deal Type: Licensing Agreement December 13, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
